U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors ...

The U.S. Food and Drug Administration (FDA) has approved Hympavzi (marstacimab-hncq) for routine prophylaxis aimed at ...

WASHINGTON, DC, UNITED STATES, October 8, 2024 /EINPresswire / -- Hemophilia Federation of America, a national nonprofit organization serving patie ...

Lundbeck A/S is to acquire Longboard Pharmaceuticals Inc. in an all-cash deal valuing the epilepsy specialist at $2.6 billion. The agreed price of $60 per share is a 54% premium to the closing price ...

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating ... reflecting the company’s diverse pipeline and the promising prospects in Hemophilia A and transthyretin amyloidosis programs.

Hemophilia A is caused by deficiency in Factor ... maintaining natural anticoagulants like protein C (PC). Unlike other therapies that risk venous or arterial thrombosis - like with Rebinyn ...

The Food and Drug Administration approved Pfizer's Hympavzi to prevent or reduce bleeding episodes in patients with certain kinds of hemophilia, the pharmaceutical company said. Write to Rob Curran at ...

Pathway to Cures (P2C) announced their annual fund update meeting on Wednesday, September 11 th in Atlanta, Georgia.

Experts explored the latest trends, approvals, and pipeline developments in cell and gene therapies, rare disease, immunology ...

25, 2024 (HealthDay News) -- A new gene therapy approved earlier this year can serve as a sustainable single-dose treatment for people with hemophilia B, newly published clinical trial data shows.

GlobalData’s report assesses the drugs in the Coagulation Factor XI pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.